ADAR1 Capital Management »

Orchard Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Orchard Therapeutics shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Orchard Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Orchard Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Orchard Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.0M 64k 16.45

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Orchard Therapeutics

Blue Owl Capital Holdings
Beryl Capital Management
Federated Investors
LMR Partners
Tudor Investment Corporation
Millennium Management
Goldman Sachs Group
CSS
ADAR1 Capital Management
Bck Capital Management
Jane Street
Jpmorgan Chase & Co
Hrt Financial
PenderFund Capital Management
FNY Investment Advisers

View all funds holding Orchard Therapeutics